New Interim Results from Phase IIIb Study Reinforce the Long-Term Safety Profile of Chugai’s Hemlibra in Hemophilia A
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that the second interim analysis results from the phase IIIb STASEY study reinforce the safety profile of Hemlibra® (emicizumab) characterized in the phase III HAVEN studies1,2,3. In the STASEY study, Hemlibra was effective with no new safety signals identified in adults and adolescents with hemophilia A with factor VIII inhibitors, which was consistent with the previously reported safety profile1. The results also suggested people on Hemlibra may be able to undergo certain minor surgeries without additional preventive coagulation factor4. These results were presented at the International Society on Thrombosis and Hemostasis (ISTH) 2020 Virtual Congress (July 12 to 14, 2020).
“I am pleased that the large clinical study data reinforce the long-term safety and tolerability of Hemlibra for the treatment of hemophilia A with inhibitors. The long-term data will provide great clinical insights for treatment with Hemlibra,” said Dr. Osamu Okuda, Chugai’s President and COO. “Hemlibra is a bispecific antibody drug with a novel mechanism of action, clearly distinct from existing drugs. We will continue our efforts to collect and report clinical data so that people with hemophilia A globally can continue to use Hemlibra with confidence.”
The second interim analysis of the STASEY study included data from 193 participants with hemophilia A with factor VIII inhibitors, who received Hemlibra prophylaxis once-weekly1. No cases of thrombotic microangiopathy (TMA) or serious thrombotic events (TEs) related to Hemlibra were reported, and no new safety signals were observed1. Thirty-three (17.1%) people reported a Hemlibra-related adverse event (AE) 1. The most common AEs, occurring in 10% or more of people in the STASEY study, were common cold symptom nasopharyngitis (12.4%), headache (11.9%), and injection-site reaction (ISR) (11.4%)1. The ISRs reported were either mild or moderate in severity and no patients discontinued due to ISR1. Annualized bleed rates (ABR) were also consistent with previously reported observations from the phase III HAVEN studies1,2,3.
A separate analysis described management and outcomes of minor and unplanned major surgeries in patients receiving Hemlibra, although not a formal surgery endpoint in STASEY. Results suggest people with hemophilia A with factor VIII inhibitors who undergo certain minor surgeries whilst receiving Hemlibra may not need additional preventative coagulation factor4. The majority of minor surgeries (n=20/31, 64.5%) were performed without the use of preventative coagulation factor and, of these, 85% (n=17/20) did not result in treated post-operative bleeds4. Of the unplanned major surgeries (n=9), eight were managed with prophylactic coagulation factor, four of which resulted in bleeds managed successfully with recombinant factor VIIa4. These findings are consistent with results observed in a previous analysis of surgeries in the pivotal HAVEN studies5.
STASEY is a single-arm, multicenter, open-label, phase IIIb clinical study where participants received Hemlibra for an average of 50.9 weeks. The ABR of all bleeds, including treated bleeds, treated spontaneous bleeds, treated joint bleeds and treated target joint bleeds were low, with 167 patients (85.6%) experiencing zero treated bleeds1. There were two TEs unrelated to Hemlibra reported. One was a ST-elevation myocardial infarction in a person with pre-existing risk factors, which the treating physician assessed as unrelated to Hemlibra1. The second was a hypertrophic clot at the site of a tooth extraction, a known complication of the procedure1.
There is no participation from Japan to the STASEY study.
Trademarks used or mentioned in this release are protected by law.
- Jimenez-Yuste V et al. Second Interim Analysis Results from STASEY Trial: A Single-arm, Multicenter, Open-Label, Phase III Clinical Trial to Evaluates the Safety and Tolerability of Emicizumab Prophylaxis in People with Hemophilia A (PwHA) with FVIII inhibitors. [poster no. PB0958] International Society on Thrombosis and Haemostasis (ISTH) 2020 Congress, 12-14 July, 2020
- Oldenburg J et al. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. NEJM 2017; 377:809-818.
- Young G et al. Emicizumab prophylaxis provides flexible and effective bleed control in children with hemophilia A with inhibitors: results from the HAVEN 2 study. Blood 2018; 132 (Supplement 1): 632.
- Castaman G et al. Surgical Experience from the Phase III STASEY Trial of Emicizumab Prophylaxis in Persons with Hemophilia A (PwHA) with FVIII Inhibitors: Data from the Second Interim Analysis. [poster no: PB0939] International Society on Thrombosis and Haemostasis (ISTH) 2020 Congress, 12-14 July, 2020
- Santagostino E et al. Surgical experience from four phase III studies (HAVEN 1–4) of emicizumab in persons with haemophilia A (PwHA) with or without FVIII inhibitors. [OC 60.1], Nurses and Orals Abstracts. Res Pract Thromb Haemost 2019; 3:1-228
Chugai Pharmaceutical Co., Ltd.
Media Relations Group, Corporate Communications Dept.,
For US media
Chugai Pharma USA Inc.
For European media
Chugai Pharma U.K. Ltd.
For Taiwanese media
Chugai Pharma Taiwan Ltd.
Chugai Pharmaceutical Co., Ltd.
Investor Relations Group, Corporate Communications Dept.,
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Researcher John Craig Venter Is Awarded the 2020 Edogawa-NICHE Prize for His Accomplishment in Human Genome Research15.8.2020 09:00:00 EEST | Press release
The Edogawa NICHE Prize for the year 2020 has been awarded to Dr. John Craig Venter for his contribution to research and development pertaining to the Human genome. This honor reflects Dr. Venter's lifetime accomplishments in the power of the genomics and specifically in the identification of the human genome which has radically transformed healthcare according to Prof. Gary Levy, chair, Edogawa NICHE awards committee (www.edogawanicheprize.org). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200814005092/en/ Dr. John Craig Venter, recipient of the 2020 - Edogawa NICHE Prize, for his contribution to research and development pertaining to the Human genome. (Photo: Business Wire) Edogawa NICHE Prize was Instituted in 2018, by the Jinseisha trust, and the Nichi-In Centre for Regenerative Medicine (NCRM), which honours scientists or clinicians whose contributions lead to the development of prevention, diagnosis or treatment of a
Eaton Launches New Line of Wireless Mobile Control Solutions for Heavy Machinery and Field Operations14.8.2020 00:51:00 EEST | Press release
Power management company Eaton today announced its eMobility business has launched a new and improved line of Eaton OMNEX Trusted Wireless™ mobile control solutions for heavy machinery and field operations. The 900 MHz two-way remote-control units allow for the wireless control of high-value machinery in harsh environments, including mining, construction, agriculture, locomotive and marine markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200813005826/en/ Eaton's new OMNEX Trusted Wireless™ controllers can remotely operate heavy machinery, such as vacuum trucks, tow trucks, concrete mixers and cranes. (Photo: Business Wire) “Our next generation of rugged, weatherproof OMNEX wireless controllers were designed with customer input, and offer a number of benefits, including enhanced safety and productivity for machine operators,” said Scott Adams, president, eMobility, Eaton. “Overall, we’ve improved upon the reliability a
IFF to Hold Virtual Special Meeting of Shareholders on August 2713.8.2020 23:15:00 EEST | Press release
Regulatory News: IFF (NYSE: IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of taste, scent, and nutrition, announced today that the previously communicated special meeting of shareholders to consider and vote on the issuance of shares of IFF common stock in connection with the previously announced proposed merger of IFF and DuPont’s Nutrition & Biosciences (“N&B”) business pursuant to a Reverse Morris Trust transaction (the “special meeting”) has been changed to a virtual-only meeting due to the continued public health concerns over the COVID-19 outbreak and the health and safety of its shareholders and employees. Accordingly, the special meeting, to be held on Thursday, August 27, 2020 at 10:00 a.m. Eastern Time, will be held only virtually on the Internet at www.virtualshareholdermeeting.com/IFF2020SM. Shareholders will not be able to attend the meeting or vote physically in person. We have designed the format of the special meeting to provide shareholders the same right
PTC Makes Enterprise Version of Onshape Education Suite Available Free of Charge13.8.2020 23:00:00 EEST | Press release
In advance of the 2020-2021 school year, PTC (NASDAQ: PTC) has made the Onshape® Education Suite’s newly-released Enterprise plan available free-of-charge for K-12 schools and universities that register through November 20, 2020. The newest version of the cloud-based, remote learning suite is offered alongside the Onshape Education Standard plan to help alleviate the burden experienced by educational STEM programs during the COVID-19 pandemic. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200813005767/en/ The Onshape Education plans are the educational versions of PTC’s Software as a Service product, designed to enable computer-aided design (CAD) activities in a remote learning environment. The Education Standard plan has been free to educational institutions since 2016 and is available to students and educators who want to use professional-grade CAD that is completely online. The newly released Education Enterprise plan bu
DeltaTrak Enhances Its Cold Chain Restart Program to Help Customers Battle COVID-1913.8.2020 19:00:00 EEST | Press release
DeltaTrak®, a leading innovator of cold chain solutions, is enhancing its Cold Chain Restart Program to offer customers safer and more efficient methods to protect their employees and clients from the COVID-19 pandemic. The program was created to help companies reopen on a safe footing by providing access to critically needed PPE solutions. Following an extremely positive response, DeltaTrak has added the ThermoTrace Auto-Check Non-Contact Infrared Forehead Thermometer and Touchless Hand Sanitizer Dispenser to address the need for effective, contactless and hands-free options for temperature measurement and sanitization. “The increased demand for safety and sanitization equipment is driven by our customers’ need to conduct business safely without jeopardizing the health of employees and customers when it comes to using thermometers and hand sanitizers,” said Frederick Wu, President and CEO of DeltaTrak. “Gaining access to these solutions remains a major challenge and we are confident t
Verimatrix to Sponsor Virtual SportsPro Media INSIDER Series Featuring Broadcasting Experts From the NFL, Octagon, Astro, The FA, European Tour & More13.8.2020 18:35:00 EEST | Press release
Regulatory News: Verimatrix (Paris:VMX) (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced that Chief Revenue Officer Lu Bolden will join a lineup of sports broadcasting experts to speak on the future of the industry with today’s new need to protect ever-growing amounts of streamed sports and esports. Registration is free. Visit www.insider.sportspromedia.com. With an eye on highlighting the largely unchartered challenges that come with new methods of reaching all types of sports fans, the SportsPro Media INSIDER Series serves as a valuable venue for those seeking to protect revenues when fans are at home instead of stadiums. Traditional sports have found themselves facing the same new business model decisions that esports has organically addressed over the last several years. That makes for a big shift – where new revenue streams are created at warp speed with various streaming and broadcast options for countless typ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom